Selected first-quarter drug sales for Merck & Co.

— Here are sales figures for the first quarter for Merck & Co.'s 10 top-selling drugs:

PRODUCT NAME CONDITION/USE 1Q 2011 SALES 1Q 2010 SALES PERCENT CHANGE

Singulair Asthma/allergies $1.33 billion $1.16 billion up 14

Januvia and Janumet Diabetes $1.04 billion $712 million up 47

Remicade Rheumatoid arthritis $753 million $674 million up 12

Zetia High cholesterol $582 million $534 million up 9

Vytorin High cholestrol $480 million $477 million up 1

Cozaar and Hyzaar High blood pressure $426 million $782 million down 46

Nasonex Allergies $373 million $320 million up 17

Isentress HIV treatment $292 million $232 million up 26

Temodar Brain cancer $248 million $274 million down 10

Gardasil HPV vaccine $214 million $233 million down 8